Peanut allergy immunotherapy - ALK-Abello
Alternative Names: Peanut allergy sublingual immunotherapy - ALK Abello; Peanut SLIT-tabletLatest Information Update: 22 Jan 2024
At a glance
- Originator ALK-Abello
- Class Allergens; Food allergy immunotherapies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase I Peanut hypersensitivity
Most Recent Events
- 19 Jan 2024 Adverse events data from a phase I ALLIANCE trial in Peanut hypersensitivity released by ALK-Abello
- 19 Jan 2024 ALK-Abello plans a phase I/II trial for Peanut hypersensitivity
- 15 Sep 2023 Phase-I clinical trials in Peanut hypersensitivity (In adolescents, In adults, In children) in Canada (Sublingual)